Launch Therapeutics will take over management of clinical trials of Teva’s TEV-‘248 fluticasone / albuterol (salbutamol) DPI for the treatment of asthma, the companies have announced. In addition, Carlyle Group subsidiary Abingworth, a Launch Therapeutics backer, will invest up to $150 million toward funding continued development of TEV-'248 and would receive … [Read more...] about Teva partners with Launch Therapeutics on development of TEV-‘248 fluticasone / albuterol DPI, with funding from Abingworth
Business
FTC tells court hearing Teva’s patent infringement case against Amneal that Teva patents listed for ProAir HFA should be de-listed
The US Federal Trade Commission (FTC) recently filed an amicus brief in a patent infringement case filed by Teva against Amneal after Amneal submitted an ANDA for a generic version of Teva's ProAir HFA albuterol MDI in July 2023. In the brief, the FTC contends that the court should grant Amneal's motion to force device and dose counter patents asserted by Teva to be … [Read more...] about FTC tells court hearing Teva’s patent infringement case against Amneal that Teva patents listed for ProAir HFA should be de-listed
Marinomed announces deals for Carragelose nasal sprays in Hungary and in Gulf countries
Marinomed Biotech has announced a new agreement with VitaPlus for distribution of one of Marionomed's Carragelose nasal sprays in Hungary and another agreement with GAIA Healthcare for marketing of two Carragelose nasal sprays in the Gulf region. According to the announcement, VitaPlus could launch the nasal spray by the end of this year, and GAIA will be submitting … [Read more...] about Marinomed announces deals for Carragelose nasal sprays in Hungary and in Gulf countries
AstraZeneca follows Boehringer Ingelheim in capping inhaler costs for some US patients
AstraZeneca has announced that it will "expand the savings programs for its entire US inhaled respiratory portfolio," capping costs at $35 per month for "eligible patients" as of June 1, 2024, while noting that "terms and conditions apply." Inhalers covered by the program include Airsupra albuterol / budesonide MDI, Bevespi Aerosphere glycopyrrolate / formoterol … [Read more...] about AstraZeneca follows Boehringer Ingelheim in capping inhaler costs for some US patients
Boehringer Ingelheim says it will limit out-of-pocket cost of its inhalers for some US patients
Boehringer Ingelheim said that "eligible patients" will pay no more than $35 per month for BI inhalers, including Atrovent HFA ipratropium MDI, Combivent Respimat ipratropium / albuterol SMI, Spiriva HandiHaler tiotropium DPI, Spiriva Respimat tiotropium SMI, Stiolto Respimat tiotropium / olodaterol SMI, and Striverdi Respimat olodaterol SMI. According to the company, … [Read more...] about Boehringer Ingelheim says it will limit out-of-pocket cost of its inhalers for some US patients
Nocion raises $62 million for Phase 2b study of taplucainium DPI for the treatment of chronic cough
Nocion Therapeutics has announced that it raised $62 million in a Series B funding led by Monograph Capital and Arkin Bio Capital. Proceeds will be used to support a Phase 2b trial of its taplucainium (NTX-1175) inhaled dry powder for the treatment of chronic cough, the company said. In January 2020, Pulmatrix said that it had signed a deal to evaluate the use of … [Read more...] about Nocion raises $62 million for Phase 2b study of taplucainium DPI for the treatment of chronic cough
Apotex recalls two lots of APO-Mometasone nasal spray
Health Canada has announced that Apotex is recalling 2 lots of its mometasone nasal spray, a generic of Nasonex, due to possible contamination with Burkholderia cepacia complex. Lot TX5343 has an expiration date of September 2025, and lot TZ2586 has an expiration date in October 2025. APO-Mometasone nasal spray is approved in Canada for the treatment of allergies … [Read more...] about Apotex recalls two lots of APO-Mometasone nasal spray
Dr. Ferrer BioPharma wins Pharmapack award for its GentleMist nasal delivery technology
The Patient-Centric Design award at CPHI Pharmapack 2024 went to Florida-based Dr. Ferrer BioPharma for its GentleMist nozzle for intranasal delivery devices, which was developed as part of a partnership with researchers at South Dakota State University, Bona Pharma, and the Cleveland Clinic. According to the company, "GentleMist Technology utilizes advanced fluid … [Read more...] about Dr. Ferrer BioPharma wins Pharmapack award for its GentleMist nasal delivery technology
AstraZeneca launches Airsupra albuterol / budesonide MDI in the US
AstraZeneca has announced the US launch of its Airsupra albuterol / budesonide MDI, which was approved by the FDA in January 2023 for the treatment of asthma in people aged 18 and over. Airsupra (PT027) was developed by AstraZeneca subsidiary Pearl Therapeutics. The company points out that the MDI is the only approved SABA/ICS inhaler and the only one that includes … [Read more...] about AstraZeneca launches Airsupra albuterol / budesonide MDI in the US
Cyrano raises $9 million for continued development of CYR-064 intranasal theophylline for the treatment of hyposmia
Cyrano Therapeutics said that the company will use proceeds from a $9 million Series B financing round to fund an ongoing Phase 2 trial of CYR-064 theophylline nasal spray for the treatment of loss of smell due to viral infection. Cyrano previously announced in December 2020 that it had raised $12.8 million in Series A financing for a Phase 2 trial of CYR-064. In … [Read more...] about Cyrano raises $9 million for continued development of CYR-064 intranasal theophylline for the treatment of hyposmia